Global Pharmaceutical Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 – Featuring Morgan Stanley, Credit Suisse & Goldman Sachs Among Others – ResearchAndMarkets.com
February 12, 2020DUBLIN–(BUSINESS WIRE)–The “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 in Pharmaceuticals” report has been added to ResearchAndMarkets.com’s offering.
This report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry.
The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2019. It portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies.
Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from the publisher’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
-
League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Key Topics Covered:
1 Table of Contents
2 Pharmaceuticals & Healthcare, Global, Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2019
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, November 2019
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2019
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2019
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2019
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2019
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2019
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2019
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2019 – November 2019
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2019
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2019 – November 2019
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2019 – November 2019
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2019 – November 2019
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2019
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2019
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2019
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2019 – November 2019
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2019 – November 2019
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2019 – November 2019
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2019 – November 2019
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2019
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2019
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2019
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2019
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2019
5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, November 2019
5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, November 2019
6 Deal Summary by Geography
6.1 Pharmaceuticals & Healthcare, North America Deals, November 2019
6.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2019
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2019
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2019
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
8 Further Information
For more information about this report visit https://www.researchandmarkets.com/r/ra0nfy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900